Introduction
In recent years, regulation of thyroid cell growth has become a topic of interest in numerous laboratories, including our own (1) (2) (3) (4) (5) (6) (7) (8) (9) . In pursuing this topic, we, like others, have employed as a model the FRTL5 line of rat thyroid follicular cells. Although capable of being maintained in continuous culture, FRTL5 cells do not display other characteristics of transformed cells, and after many years in culture, they retain many of the differentiated functions of the thyroid follicular cell in vivo (1) . Although the growth of FRTL5 cells has been thought to be almost entirely dependent upon the presence of thyrotro-pin-stimulating hormone (TSH), other agents that increase effective levels of intracellular cAMP, as TSH does, also stimulate DNA synthesis (5, 6, 9) . Moreover, recombinant insulinlike growth factor I (IGF-I),' which does not increase intracellular cAMP concentration in FRTL5 cells (9) , none- theless has an independent action to increase DNA synthesis and replication in these cells and, most importantly, synergizes the effect of TSH to increase DNA synthesis (8) .
In examining the characteristics of the interactions between IGF-I and the cAMP-mediated growth pathway, we conducted studies of the effects of sm-1.2, a monoclonal anti-IGF antibody. Effects of this antibody on the growth of FRTL5 cells and their responses to various mitogens raised the strong possibility that these cells produce an immunoreactive IGF. We therefore performed experiments to examine this question directly and, in so doing, obtained evidence that the cells do indeed produce rat IGF-II (rIGF-II). This, in turn, led us to additional studies of the functional significance of the endogenous IGF. The evidence that FRTL5 cells produce rIGF-II, that this endogenous IGF-I1 acts as an autocrine growth factor, and that it also conditions the response to other mitogens constitutes the substance of this report. A portion of these results has been presented in abstract form (10).
Methods
Special reagents. Monoclonal antibody to IGF-I (sm-1.2) was generously provided by Dr. Judson J. Van Wyk (University of North Carolina, Chapel Hill, NC). This antibody cross-reacts with human IGF-II (hIGF-II) and rIGF-II (MSA-HII-2) to the extent of -5 and 1%, respec- tively, but does not cross-react with insulin (1 1), a finding confirmed in our laboratory. Polyclonal antiserum to human IGF-I (hIGF-I) for use in RIAs was kindly provided by Dr. Richard W. Furlanetto (University of Pennsylvania, Philadelphia, PA). This antiserum reacts with the IGF-I of many species, including that of the rat. It is highly specific for IGF-I, having < 5% cross-reactivity with hIGF-II or rIGF-II (12, 13).
The polyclonal antibody to rIGF-II used for RIAs cross-reacts with IGF-I and hIGF-II to the extent of -3 and 10%, respectively, but does not cross-react with insulin (14) . rIGF-II (7, three "hormones": bTSH (1 mU/ml), insulin (1 /Ag/ml), and transferrin (5 og/ml) (3H medium). Cells were cultured in 250-ml flasks or 24-well plates at 370C in an atmosphere of 95% air-5% CO2 in a humidified incubator as described previously (1 (21) . Samples for analysis prepared either by G-50 or by Sep-Pak chromatography were redissolved in assay buffer for analysis, the quantity added to each assay tube being equivalent to 4 ml of original unconcentrated medium. For assay of IGF-I, we used a technique previously described, with minor modifications (22) . hIGF-I was used as the radioligand and Thr59-IGF-I as a standard (21) . The antibody against IGF-I was employed in a final dilution of 1:20,000 and the separation method was precipitation with goat anti-rabbit gamma globulin in the presence of 6% polyethylene glycol. The sensitivity ofthe assay was 0.1 ng/tube. rIGF-II was assayed by the method of Moses et al. ( 14) . The antiserum was used in a final dilution of 1:1,000, and the assay sensitivity was 1 ng/tube.
[3H]Thymidine incorporation. Studies of [3H]thymidine incorporation into DNA were performed as described previously (9) . FRTL5 cells were studied [5] [6] [7] (23) .
Binding of'25I-bTSH. bTSH was labeled by a gentle chloramine T technique, as previously described (24), to a specific activity of 150 ,sCi/Og. '251-bTSH binding to confluent FRTL5 cells was performed (9, 23) in a modified KRB in which NaCl was replaced by sucrose in sufficient concentration (280 mM) to maintain the tonicity of the solution (modified KRB) as described previously (9, 23 (Fig. 2) . At a concentration of 1 gg/ml, insulin induced a greater stimulation of [3H]-thymidine incorporation than 100 ng/ml rIGF-II did; nonetheless, the enhancement of the TSH response by insulin was much less marked than that produced by rIGF-II. (Fig. 4) tested, sm-1.2 had no effect on the mitogenic response to insulin (Fig. 4) . In experiments with varying concentrations of rIGF-II and insulin, the independent mitogenic effect of each was confirmed (26). Further, IGF-I did not amplify the effects of these mitogens (data not shown), as it did in the case of TSH (9) .
Response to TSH. In what we initially assumed would be negative control studies, we examined the effect of sm-1.2 on the mitogenic response to bTSH. As expected, increasing concentrations of bTSH produced a dose-dependent stimulation of [3H]thymidine incorporation into DNA that, surprisingly, was inhibited by sm-1.2. At a concentration of 10 /ig/ml, sm-1.2 inhibited the response to 10-9 M bTSH by -50%. Normal mouse IgG had no effect.
Additional studies were conducted in which the effects of varying concentrations of bTSH and sm-1.2, alone and in combination, were assessed concomitantly (Fig. 5) . In these experiments, the inhibitory effect of each concentration of antibody was greatest at the lower concentrations of bTSH and least at the higher concentrations of bTSH. Further, for each concentration of bTSH, we observed a concentration of antibody beyond which no further inhibition of the response to bTSH was observed. As a result, in these maximally inhibited specimens, a dose-dependent stimulatory effect of bTSH on
[3H]thymidine incorporation was preserved.
Ensuing experiments were conducted in an effort to ascertain the mechanism by which the anti-IGF antibody sm-1.2 inhibited the mitogenic responses to bTSH. When added directly to the radioreceptor assay mixture, a concentration of sm-1.2 that strongly inhibited the mitogenic response to high concentrations of bTSH had no effect whatsoever on the binding of tracer concentrations of '251-bTSH (data not shown). Because the stimulation of DNA synthesis that bTSH produces in quiescent FRTL5 cells evidently depends on the increase in cellular cAMP concentration that it produces (5, 6, 10), experiments were conducted to determine whether sm-1.2 would modify this response; however, no alteration of the cAMP response to bTSH by sm-1.2 was observed (data not shown).
Responses to Bt2cAMP, forskolin, cholera toxin, and Graves'-IgG. Because the mitogenic effect of bTSH in quiescent FRTL5 cells is mimicked by other agents that increase the effective intracellular cAMP concentration (10), we examined the effect of sm-1 .2 on the ability of these agents to stimulate [3H]thymidine incorporation into DNA. As anticipated, cholera toxin, forskolin, and Bt2cAMP, tested at their maximally effective concentrations (10), as well as Graves'-IgG (9), were all stimulatory to DNA synthesis, and their effects all were inhibited in a concentration-dependent manner by sm-1.2 (Fig. 6) .
Cell replication. Studies were conducted to determine the effects of the anti-IGF antibody sm-1.2 on the stimulation of cell replication induced by bTSH, IGF-I, and insulin (Fig. 7) . In four separate observations, cell counts at 5 d in specimens treated with bTSH were 394±8.3% those in control specimens; this increase was significantly diminished (P < 0.001) by the addition of sm-1.2, since cell counts in the presence of sm-1.2 were only about double those in controls (Fig. 7) . A smaller enhancement ofcell replication was produced by IGF-I, which increased cell counts to an average of 148±6.9% of those in control wells. As (Fig. 8) .
In view of the possibility that the effect of sm- In contrast, sm-1.2 did inhibit the independent mitogenic responses to Bt2cAMP, forskolin, cholera toxin, and Graves' IgG, all of which increase the effective intracellular cAMP concentration. The effect of these agents, like that of TSH, is amplified by IGF-I and IGF-II (8, 9) . Therefore, the ability of sm-1.2 to inhibit the response to these agents supports our earlier suggestion that the amplifying interaction between the cAMP-dependent pathway activated by TSH and the cAMPindependent pathway activated by IGF takes place at some post-cAMP site (9, 27) .
Observations with sm-1.2 may also shed some light on the biology of the M12 mutant cells, which grow vigorously in the absence of TSH. These cells condition their media with concentrations of rIGF-II four to five times higher than those found in media conditioned by FRTL5 cells, and the media conditioned by M12 cells have a more pronounced stimulatory effect on both basal and TSH-stimulated [3H]thymidine incorporation in quiescent FRTL5 cells than media conditioned by FRTL5 cells. Moreover, basal thymidine incorporation in these cells, which is substantial as a reflection of their spontaneous growth, is greatly inhibited by the addition of sm-1.2, and cell replication is greatly retarded by the antibody.
These findings raise the possibility that the capacity ofM12 mutant cells to grow spontaneously may reflect, at least partly, the high level of rIGF-II that they produce. This is not to suggest, however, that the mutation that makes these cells independent of TSH is one that results solely in enhanced production of IGF-II. Indeed, the nature of the mutation remains uncertain.
There is a clear and increasing precedent for the presence of a variety of autocrine growth factors within different tissues (28-46). With respect to the IGFs, several studies have presented evidence of their release into the medium by cells in tissue culture (28-35). Further, recent studies have provided evidence for the synthesis of IGFs in rat and human tissues, as judged from measurements of tissue concentration and the demonstration of the cellular localization of specific mRNAs by in situ hybridization, respectively (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) .
A precedent also exists for an endogenous IGF to modify the response to an exogenous growth factor. In studies of porcine aortic smooth muscle cells and human fibroblasts, Clemmons and Van Wyk have found that sm-1.2, the same anti-IGF antibody that we used, significantly inhibited both basal thymidine incorporation and the mitogenic response to platelet-derived growth factor (47). These findings led to the suggestion that platelet-derived growth factor-induced mitogenesis in these cell types is due in part to stimulation of the production of an IGF-like peptide. We have no information concerning the extent to which mitogenic agents whose action in FRTL5 cells is cAMP-mediated may exert their effect by increasing the synthesis of the endogenous IGF-II, which then stimulates growth. In all likelihood, however, this is not a major mechanism by which agents like bTSH stimulate growth in FRTL5 cells. First, the persistence of a dose-dependent mitogenic effect of TSH in the presence of increasing amounts of anti-IGF antibody strongly indicates that TSH was exerting an independent mitogenic effect. Second, the increase in [3H]thymidine incorporation into DNA in FRTL5 cells induced by the addition of synergistic concentrations of TSH and IGF-I is far in excess of the concomitantly measured response to maximally effective concentrations of IGF-I alone (9) .
With respect to the thyroid cell, studies in primary cultures derived from different species, such as the dog, sheep, human, pig, and rat, have shown that growth factors, such as insulin and epidermal growth factor, have an independent stimulatory effect on growth and augment the response to TSH (1-3, 7, 48-50) . However, in none of these instances has it been shown that the cell type that responds to epidermal growth factor or insulin produces either of the two growth factors. Conversely, ours is not the first demonstration of the production of IGF-I by a thyroid cell, since Mak and co-workers have reported synthesis of IGF-I by ovine thyroid cells in primary culture (51) . However, these investigators did not provide any evidence that this endogenous IGF-I subserves a significant functional role in the ovine thyroid cell.
The most interesting questions that arise from these findings are whether one or another IGF is produced by the thyroid in the living animal, and if so, whether it acts as a mitogen locally, whether it modifies the response to TSH, and how its production is regulated.
